BACKGROUND: Polypharmacy carries the risk of adverse events, especially in people with multimorbidity. OBJECTIVE: To investigate the prevalence of polypharmacy in community-dwelling adults, the association of multimorbidity with polypharmacy and the use of medications for primary prevention. METHODS: Cross-sectional analysis of the follow-up data from the Program of Research on the Evolution of a Cohort Investigating Health System Effects (PRECISE) in Quebec, Canada. Multimorbidity was defined as the presence of three or more chronic diseases and polypharmacy as self-reported concurrent use of five or more medications. Primary prevention was conceptualized as the use of statin or low-dose antiplatelets without a reported diagnostic of cardiovascular disease. RESULTS: Mean age 56.7 ± 11.6, 62.5% female, 30.3% had multimorbidity, 31.9% had polypharmacy (n = 971). The most common drugs used were statins, renin-angiotensin system inhibitors and psychotropics. Compared to participants without any chronic disease, the adjusted odds ratios (ORs) for having polypharmacy were 2.78 [95% confidence interval (CI): 1.23-6.28] in those with one chronic disease, 8.88 (95% CI: 4.06-19.20) in those with two chronic diseases and 25.31 (95% CI: 11.77-54.41) in those with three or more chronic diseases, P < 0.001. In participants without history of cardiovascular diseases, 16.2% were using antiplatelets and 28.5% were using statins. Multimorbidity was associated with increased likelihood of using antiplatelets (adjusted OR: 2.98, 95% CI: 1.98-4.48, P < 0.001) and statins (adjusted OR: 3.76, 95% CI: 2.63-5.37, P < 0.001) for primary prevention. CONCLUSION: There was a high prevalence of polypharmacy in community-dwelling adults in Quebec and a strong association with multimorbidity. The use of medications for primary prevention may contribute to polypharmacy and raise questions about safety.
BACKGROUND: Polypharmacy carries the risk of adverse events, especially in people with multimorbidity. OBJECTIVE: To investigate the prevalence of polypharmacy in community-dwelling adults, the association of multimorbidity with polypharmacy and the use of medications for primary prevention. METHODS: Cross-sectional analysis of the follow-up data from the Program of Research on the Evolution of a Cohort Investigating Health System Effects (PRECISE) in Quebec, Canada. Multimorbidity was defined as the presence of three or more chronic diseases and polypharmacy as self-reported concurrent use of five or more medications. Primary prevention was conceptualized as the use of statin or low-dose antiplatelets without a reported diagnostic of cardiovascular disease. RESULTS: Mean age 56.7 ± 11.6, 62.5% female, 30.3% had multimorbidity, 31.9% had polypharmacy (n = 971). The most common drugs used were statins, renin-angiotensin system inhibitors and psychotropics. Compared to participants without any chronic disease, the adjusted odds ratios (ORs) for having polypharmacy were 2.78 [95% confidence interval (CI): 1.23-6.28] in those with one chronic disease, 8.88 (95% CI: 4.06-19.20) in those with two chronic diseases and 25.31 (95% CI: 11.77-54.41) in those with three or more chronic diseases, P < 0.001. In participants without history of cardiovascular diseases, 16.2% were using antiplatelets and 28.5% were using statins. Multimorbidity was associated with increased likelihood of using antiplatelets (adjusted OR: 2.98, 95% CI: 1.98-4.48, P < 0.001) and statins (adjusted OR: 3.76, 95% CI: 2.63-5.37, P < 0.001) for primary prevention. CONCLUSION: There was a high prevalence of polypharmacy in community-dwelling adults in Quebec and a strong association with multimorbidity. The use of medications for primary prevention may contribute to polypharmacy and raise questions about safety.
Authors: Richard Ofori-Asenso; Ken Lee Chin; Andrea J Curtis; Ella Zomer; Sophia Zoungas; Danny Liew Journal: Popul Health Manag Date: 2018-08-10 Impact factor: 2.459
Authors: Gotaro Kojima; Christina Bell; Bruce Tamura; Michiko Inaba; Karen Lubimir; Patricia Lanoie Blanchette; Wendy Iwasaki; Kamal Masaki Journal: J Am Med Dir Assoc Date: 2012-09-05 Impact factor: 4.669
Authors: Beth A Parker; Jeffrey A Capizzi; Adam S Grimaldi; Priscilla M Clarkson; Stephanie M Cole; Justin Keadle; Stuart Chipkin; Linda S Pescatello; Kathleen Simpson; C Michael White; Paul D Thompson Journal: Circulation Date: 2012-11-26 Impact factor: 29.690
Authors: Fernanda Esthefane Garrides Oliveira; Rosane Harter Griep; Dora Chor; Luana Giatti; Luciana A C Machado; Sandhi Maria Barreto; Alexandre da Costa Pereira; Maria de Jesus Mendes da Fonseca; Leonardo Soares Bastos Journal: BMC Public Health Date: 2022-07-09 Impact factor: 4.135
Authors: Anna Pefoyo Kone; Luke Mondor; Colleen Maxwell; Umme Saika Kabir; Laura C Rosella; Walter P Wodchis Journal: Can J Public Health Date: 2021-04-13
Authors: Louis Jacob; Jae Il Shin; Karel Kostev; Josep Maria Haro; Guillermo F López-Sánchez; Lee Smith; Ai Koyanagi Journal: J Clin Med Date: 2022-07-31 Impact factor: 4.964